

22 November 2022

ASX Announcement

RESULTS OF ANNUAL GENERAL MEETING

MELBOURNE Australia, 22 November 2022: AdAlta Limited (ASX:1AD), the clinical stage drug discovery company developing novel therapeutic products from its i-body platform advises that its Annual General Meeting was held today at 11:00am AEDT.

In accordance with Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act 2001 (Cth), the Company advises that details of the resolutions and the votes received in respect of each resolution are set out in the attached summary. All resolutions were carried.

Authorised for lodgement by:

Tim Oldham
CEO and Managing Director
November 2022

Notes to Editors About AdAlta

AdAlta Limited is a clinical stage drug development company headquartered in Melbourne, Australia. The Company is using its proprietary i-body technology platform to solve challenging drug targeting problems and generate a promising new class of single domain antibody protein therapeutics with the potential to treat some of today's most challenging medical conditions.

The i-body technology mimics the shape and stability of a unique and versatile antigen binding domain that was discovered initially in sharks and then developed as a human protein. The result is a range of unique proteins capable of interacting with high selectivity, specificity and affinity with previously difficult to access targets such as G-protein coupled receptors (GPCRs) that are implicated in many serious diseases. i-bodies are the first fully human single domain antibody scaffold and the first based on the shark motif to reach clinical trials.

AdAlta has completed Phase I clinical studies for its lead i-body candidate, AD-214, that is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases for which current therapies are sub-optimal and there is a high unmet medical need. AdAlta has a second target in discovery research, also in the field of fibrosis and inflammation.

The Company is also entering collaborative partnerships to advance the development of its i-body platform. It has a collaboration with Carina Biotech to co-develop precision engineered, i-body enabled CAR-T cell therapies (i-CAR-T) to bring new hope to patients with cancer. It has an agreement with GE Healthcare to co-develop i-bodies as diagnostic imaging agents (i-PET imaging) against Granzyme B, a biomarker of response to immune-oncology drugs, a program now in pre-clinical development.



AdAlta's strategy is to maximise the products developed using its next generation i-body platform by internally discovering and developing selected i-body enabled product candidates against GPCRs implicated in fibrosis, inflammation and cancer and partnering with other biopharmaceutical companies to develop product candidates against other classes of receptor, in other indications, and in other product formats.

Further information can be found at: <https://adalta.com.au>

For more information, please contact:

Investors

Tim Oldham, CEO & Managing Director
Tel: +61 403 446 665
E: t.oldham@adalta.com.au

Media

IR Department
Tel: +61 411 117 774
E: jane.lowe@irdepartment.com.au

Disclosure of Proxy Votes

AdAlta Limited

Annual General Meeting

Tuesday, 22 November 2022



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results (if applicable)		
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
1 Adoption of Remuneration Report	P	172,905,325	169,981,310 98.31%	2,902,884 1.68%	1,277,833	21,131 0.01%	183,002,940 98.44%	2,902,884 1.56%	1,277,833
2 Re-election of Director –Mr Paul MacLeman	P	175,572,285	174,347,081 99.30%	1,188,638 0.68%	63,999	36,566 0.02%	186,187,001 98.42%	2,988,638 1.58%	573,535
3 Ratification of Prior Issue of Placement Shares issued under Listing Rule 7.1	P	151,516,771	151,236,602 99.82%	240,038 0.16%	2,532,267	40,131 0.03%	155,079,824 99.85%	240,038 0.15%	2,532,267
4 Ratification of Prior Issue of Placement Shares issued under Listing Rule 7.1A	P	124,055,989	123,775,820 99.77%	240,038 0.19%	2,532,267	40,131 0.03%	137,928,841 99.83%	240,038 0.17%	2,532,267
5 Approval of 10% placement capacity	P	174,473,880	172,679,473 98.97%	1,744,276 1.00%	1,162,404	50,131 0.03%	186,842,494 99.08%	1,744,276 0.92%	1,162,404
6 Renewal of Omnibus Equity Plan	P	172,453,696	169,783,852 98.45%	2,629,713 1.52%	1,227,712	40,131 0.02%	182,824,482 98.58%	2,629,713 1.42%	1,227,712

